Streetbeat News

Products Services

CALT

Calliditas has submitted a supplemental application for full approval of Tarpeyo (Budesonide) for the entire population from the Phase 3 Neflgard study. Tarpeyo currently has accelerated approval to reduce proteinuria in IgA nephropathy patients.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 8:14 am

MSCI

MSCI Inc. has announced the launch of Quantitative Investment Solutions (QIS), a new set of tools designed to help portfolio managers efficiently customize separately managed account (SMA) portfolios at scale.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 8:09 am

CWAN

Apollo, a leading Lloyd's insurer with $500 million in AUM, has chosen Clearwater Analytics (NYSE:CWAN) to automate and streamline their investment accounting processes, including data aggregation, trade reconciliation, and reporting on a single integrated platform.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 8:08 am

XPEV

XPENG (NYSE:XPEV) has selected ACCESS Twine4Car in-vehicle infotainment (IVI) solution to provide apps, games, and streaming services for its new range of electric vehicles, starting with the XPENG P7 sedan. Existing XPENG drivers can upgrade their cars to include Twine4Car IVI through an OTA software update.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 8:05 am

ARGX

HALO

The FDA has approved Argenx's Vyvgart Hytrulo (Efgartigimod Alfa and Hyaluronidase-qvfc) for generalized myasthenia gravis. The drug utilizes Halozyme's ENHANZE drug delivery technology.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 8:02 am

ILMN

The Lancet Oncology published results from the SYMPLIFY study of Grail's multi-cancer early detection test in symptomatic patients, showing an overall cancer signal origin prediction accuracy of 85.2%. Grail is an Illumina company.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 7:59 am

META

Elon Musk taunted Mark Zuckerberg and the Dalai Lama over the development of a Twitter-like app by Facebook's parent company, Meta Platforms Inc. (NASDAQ:META). The app, known as 'Project 92' and 'Threads', is being developed to compete with Twitter and is in talks with celebrities like Oprah Winfrey and the Dalai Lama for its launch.

Portfolio Pulse from Rounak Jain

June 21, 2023 | 7:54 am

RTX

RTX's Collins Aerospace business has signed a multi-year FlightSense flight-hour contract with Envoy Air to provide maintenance, repair, and overhaul (MRO) services for various systems across Envoy's fleet of 128 Embraer E175 aircraft.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 7:40 am

CALT

Everest Medicines' partner Calliditas Therapeutics presented data from the NefIgArd Phase 3 clinical trial at the European Renal Association Congress. The trial, evaluating Nefecon in patients with IgA nephropathy, met its primary endpoint with a highly significant benefit over placebo.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 7:36 am

PFE

The FDA has approved Pfizer's Talzenna (Talazoparib) in combination with Xtandi (Enzalutamide) for the treatment of homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 7:34 am